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Objectives: The purpose of this study was to determine the levels of isoniazid and ethionamide resistance and
to identify associated mutations in endemic multidrug-resistant (MDR) strains of Mycobacterium tuberculosis
from the Lisbon metropolitan area, Portugal.
Methods: Seventeen clinical MDR tuberculosis (TB) strains were characterized by standard and semi-quantita-
tive drug susceptibility testing to assess the level of isoniazid and ethionamide resistance. The genes katG, inhA,
ethA and ndh were screened for mutations. All strains were genotyped by 24 loci mycobacterial interspersed
repetitive unit–variable number of tandem repeats (MIRU-VNTR) analysis.
Results: All strains showed high-level resistance to both isoniazid (.1 mg/L) and ethionamide (.25 mg/L).
MIRU-VNTR typing revealed the presence of two main clusters, Lisboa3 and Q1, in 16/17 strains, all of which
showed the C215T mutation in the promoter region of the inhA gene. The 16 strains belong to the Latino-
American-Mediterranean (LAM) genotype and the other strain belongs to the Beijing genotype. Sequencing
of the inhA open reading frame revealed that the 16 strains also had mutations in the structural region of
the gene, leading to the S94A substitution in 9 strains and the I194T substitution in 7 strains.
Conclusions: The results reveal that the presence of a mutation in the inhA regulatory region together with a
mutation in the inhA coding region can lead to the development of high-level isoniazid resistance and cross-
resistance to ethionamide among the MDR-TB strains circulating in Lisbon. This mutational pattern also hints
to a possible involvement of strain-specific factors that could be a feature of the Portuguese MDR-TB strains
where the LAM family is the major circulating genotype.
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Introduction
Isoniazid is one of the most effective drugs for the treatment of
tuberculosis (TB). Ethionamide is a second-line drug used in the
treatment of multidrug-resistant (MDR) TB. Both compounds
are pro-drugs that need activation by different enzymes but
share common pathways, which can lead to cross-resistance.
The majority of the mutations responsible for high-level isoniazid
resistance in Mycobacterium tuberculosis are found in the katG
gene.1 The second most commonly found mutations are observed
in the promoter of inhA.1 These mutations increase InhA
expression and confer low-level resistance to isoniazid
(0.1,MIC,1.0 mg/L).2 Mutations in the inhA promoter also
confer resistance to ethionamide, whose activity against
M. tuberculosis depends on activation by EthA.3 In addition to
inhA promoter mutations, decreased susceptibility to isoniazid
and ethionamide is associated with mutations in the structural
region of inhA that decrease the affinity to the drug–NAD adduct.2
In Portugal, the incidence rate of TB is high and the preva-
lence of MDR-TB and extensively drug-resistant (XDR) TB in the
Lisbon region is a cause of major concern.4 More than 90% of
these strains show high-level isoniazid resistance associated
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with the C215T inhA promoter mutation. This genotype was also
related with the high prevalence of ethionamide resistance.5 To
address the apparent incomprehensiveness between the level
of isoniazid and ethionamide resistance in these strains and
their mutation profile, we analysed the level of resistance
towards isoniazid and ethionamide and identified associated
mutations in MDR-TB strains isolated during 2009–11 at the
Mycobacteriology Laboratory of the Instituto de Higiene e Medi-
cina Tropical, Universidade Nova de Lisboa.
Materials and methods
Strains
Seventeen clinical strains of M. tuberculosis were included in the study
(see Table 1). The isolates were obtained from different patients with
active TB from hospitals in the Lisbon region and correspond to all
MDR-TB strains received in our laboratory during 2009–11 for identifica-
tion and first-line susceptibility testing. The selection criterion for this
study was only MDR strains. All isolates were identified using the AccuP-
robe MTBC test (GenProbe Inc., San Diego, CA, USA) according to the
manufacturer’s instructions. The M. tuberculosis reference strain H37Rv
ATCC27294T was included as the control.
Susceptibility testing
First-line susceptibility testing was carried out with the BACTECTM MGITTM
960 system (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) for
streptomycin, isoniazid, rifampicin, ethambutol and pyrazinamide,
according to the manufacturer’s instructions. Semi-quantitative drug
susceptibility testing of isoniazid and ethionamide was conducted using
the MGIT 960 system and EpiCenter V5.80A software equipped with
the TB eXIST module (Becton Dickinson), as previously described.6,7
Detection of mutations associated with resistance
Genomic DNA was extracted using the QIAamp DNA Mini Kit (QIAGEN
GmbH, Hilden, Germany) according to the manufacturer’s instructions.
The most common mutations in the structural katG gene and in the
inhA regulatory region were investigated using Genotype MTBDRplus
(Hain Lifescience GmbH, Germany) according to the manufacturer’s
instructions. Nucleic acid analysis of the complete inhA, katG and ethA
genes and an internal fragment of the ndh gene (nt 560–931) (for a
list of the primers and conditions see Table S1, available as Supplemen-
tary data at JAC Online) was performed by DNA sequencing.
Strain typing
Mycobacterial interspersed repetitive unit–variable number of tandem
repeats (MIRU-VNTR) genotyping was performed by multiplex PCR amp-
lification of 24 loci, as described by Supply et al.8 The genotype of
these strains was analysed using the MIRU-VNTRplus web application9
and the SITVITWEB database10 when relevant.
Results
The quantitative isoniazid resistance levels were determined for
the 17 MDR-TB isolates and the results are summarized in
Table 1. All isolates display isoniazid resistance levels .1 mg/L.
According to the Genotype MTBDRplus assay, 16 of the 17
strains contain a mutation the inhA promoter region (C215T);
one strain (MTB12) has a mutation in the katG gene (S315T).
The entire katG gene was sequenced for a selected group of
strains (MTB2, 4, 5, 9, 10 and 13–17), but no mutation was
found. The C215T mutation is described to confer cross-
resistance to ethionamide. All isolates show high-level ethiona-
mide resistance (.25 mg/L) (Table 1). Sequencing of the inhA
open reading frame (ORF) revealed that all strains in addition
to the C215T mutation in the inhA promoter harbour point
mutations in the inhA structural gene (Table 1). Nine of these iso-
lates carry the S94A mutation. In the remaining seven isolates,
we detected the I194T mutation. The single isolate with a muta-
tion in katG, in addition carries a mutation previously described in
ethA, S266R.11 No mutation was found in the region of the ndh
gene analysed.
Analysis of the 17 strains by MIRU-VNTR typing revealed
that 16/17 strains represent two clusters, cluster Lisboa3 and
cluster Q1 (Figure 1). These 16 strains can be assigned to the
Latino-American-Mediterranean (LAM) genotype and the
remaining 1 to the Beijing genotype. Cluster Lisboa3 comprised
the nine strains with the C215T/S94A mutations and the seven
strains with the C215T/I194T substitutions were clustered in
Q1 (Figure 1).
Discussion
In the present study, we determined the levels of resistance to
isoniazid and ethionamide for all MDR-TB strains isolated from
2009 to 2011 in our laboratory and we searched for mutations
in target genes associated with resistance to isoniazid and ethio-
namide. We found that 16 strains have cumulative mutations in
the inhA gene: the C215T mutation in the regulatory region
coupled with mutations in the structural region of the gene,
leading to the S94A and I194T substitutions. The presence of
the mutation C215T has been reported to confer low-level re-
sistance to isoniazid and cross-resistance to ethionamide.1 The
mutations S94A2 and I194T12,13 have also been reported to
cause isoniazid resistance and both were associated with low-
level resistance to isoniazid.11,13 However, there are few reports
on the combinations C215T/S94A3,11 and C215T/I194T.12 The
double mutation C215T/S94A has been reported to confer low-
level resistance,11 while the C215T/I194T combination was iden-
tified in one isolate with high-level resistance to isoniazid.12 All
16 strains with a double mutation studied in our work exhibit
high-level resistance to both isoniazid and ethionamide. In an
attempt to compare the level of resistance of these strains car-
rying double mutations with the resistance level of strains carry-
ing only the C215T mutation, we searched for additional
isoniazid-resistant strains in our laboratory isolated during the
same period. This C215T mutation alone was found among
non-MDR strains and was correlated with low-level resistance
to isoniazid (data not shown).
MIRU-VNTR typing of the strains showed the presence of two
main clusters, Lisboa3 and Q1, indicating that the dissemination
of these strains is clonal. However, the mutational profile related
to drug resistance indicates that the acquisition of drug
resistance-associated mutations is non-clonal (data not
shown), except for isoniazid and rifampicin. Thus, resistance to
isoniazid has been transmitted clonally, as all strains share the
same C215T mutation and the S94A/I194T mutations were
acquired subsequent to the C215T mutation. Sixteen out of 17
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strains were found to belong to the LAM genotype, previously
shown to be the main genotype circulating in Portugal.5,14
Fenner et al.15 recently proposed that the genetic background
of a strain may influence the level of resistance to isoniazid
conveyed by particular drug resistance-conferring mutations.
Our results suggest that these two mutations, when combined
with the C215T mutation, can act synergistically to confer high-
level resistance in this particular group of strains. All non-MDR
Table 1. Quantitative drug susceptibility profile of isoniazid and ethionamide and associated mutations in the 17 M. tuberculosis isolates
Strain Standard DST profile
INH qDST (mg/L)
ETH qDST
(mg/L) Gene mutations
0.1 0.4 1 3 10 5 10 25 inhAprom inhA ORF katG ethA ndh
H37Rv INHS, RIFS, STRS, ETBS, PZAS S S S S S S S S none none none none none
MTB1 INHR, RIFR, STRR, ETBS, PZAR R R R S S R R R C215T S94A none none none
MTB2 INHR, RIFR, STRR, ETBS, PZAS R R R S S R R R C215T S94A none none none
MTB3 INHR, RIFR, STRR, ETBS, PZAS R R R S S R R R C215T S94A none none none
MTB4 INHR, RIFR, STRR, ETBS, PZAR R R R S S R R R C215T S94A none none none
MTB5 INHR, RIFR, STRR, ETBR, PZAR R R R S S R R R C215T I194T none none none
MTB6 INHR, RIFR, STRR, ETBR, PZAR R R R S S R R R C215T I194T none none none
MTB7 INHR, RIFR, STRR, ETBS, PZAR R R R S S R R R C215T I194T none none none
MTB8 INHR, RIFR, STRR, ETBS, PZAR R R R S S R R R C215T S94A none none none
MTB9 INHR, RIFR, STRR, ETBR, PZAR R R R R R R R R C215T S94A none none none
MTB10 INHR, RIFR, STRR, ETBR, PZAR R R R S S R R R C215T I194T none none none
MTB11 INHR, RIFR, STRR, ETBR, PZAR R R R S S R R R C215T S94A none none none
MTB12 INHR, RIFR, STRR, ETBR, PZAR R R R R R R R R none none S315T S266R none
MTB13 INHR, RIFR, STRR, ETBR, PZAR R R R I S R R R C215T I194T none none none
MTB14 INHR, RIFR, STRR, ETBR, PZAR R R R S S R R R C215T S94A none none none
MTB15 INHR, RIFR, STRR, ETBR, PZAS R R R S S R R R C215T S94A none none none
MTB16 INHR, RIFR, STRR, ETBR, PZAR R R R S S R R R C215T I194T none none none
MTB17 INHR, RIFR, STRR, ETBR, PZAR R R R S S R R R C215T I194T none none none
MTB, M. tuberculosis; DST, drug susceptibility testing; qDST, quantitative drug susceptibility testing; prom, promoter; INH, isoniazid; ETH, ethionamide;
RIF, rifampicin; STR, streptomycin; ETB, ethambutol; PZA, pyrazinamide; R, resistant; I, intermediate; S, susceptible.
Results in bold indicate that the entire gene was sequenced.
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Figure 1. Cladogram based on 24 loci MIRU-VNTR of the 17 MDR M. tuberculosis isolates from Lisbon, Portugal. The grey box highlights clusters Q1 and
Lisboa3 (both belonging to the LAM genotype). From left to right are shown lineage, strain number and MIRU-VNTR profile. The linkage distance scale is
indicated at the bottom. LAM, Latino-American-Mediterranean; MTB, M. tuberculosis.
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strains evaluated during the period of this study, with low-level
resistance to isoniazid, belong to the LAM genotype, with only
one belonging to Lisboa3 (data not shown). The single strain
with a KatG S315T alteration is positioned in a completely separ-
ate branch and comprises the only Beijing strain found. From this
we conclude that strain MTB12 is a foreign strain imported into
the Lisbon area, not being part of the endemic circulating MDR
clones. Comparison of the 12 loci MIRU with the SITVITWEB
showed that MTB12 possess the MIRU international type
MIT83, which corresponds to a modern Beijing type.
Given the high-level ethionamide resistance observed in our
isolates, the inclusion of ethionamide in second-line treatment
regimens will have no benefit and other therapeutic combina-
tions must be considered.16 Our data point to the need for
rapid diagnostic methods for the detection of these strains and
strong laboratory support to provide timely and accurate drug re-
sistance information to guide the implementation of appropriate
therapy.4 While our study is limited by the size of the sample
evaluated, the strains investigated account for 45% of all the
MDR-TB strains isolated in Lisbon during this period.17 – 19
In conclusion, we report that the presence of a mutation in
the inhA regulatory region together with a mutation in the
inhA coding region is associated with high-level resistance to
both isoniazid and ethionamide among the MDR-TB strains circu-
lating in Lisbon. Furthermore, we demonstrate that MDR-TB
cases in Lisbon continue to be caused by a closely related
family of strains, identified several years ago as being associated
with MDR/XDR-TB.20 This mutational pattern also suggests the
involvement of strain-specific factors that could be a feature of
Portuguese MDR-TB strains with relevance for their appropriate
treatment.
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